COMMUNIQUÉS West-GlobeNewswire

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

04/11/2024 - 13:30

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment [...]

ElevateBio Appoints Amy Pooler, Ph.D., as Senior Vice President, Research and Development

04/11/2024 - 13:30

Dr. Pooler brings decades of scientific leadership and expertise in the discovery and development of transformative genetic medicines WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ElevateBio, LLC (ElevateBio), a [...]

Aveanna Healthcare Holdings Announces Appointment of New Director

04/11/2024 - 13:30

ATLANTA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today [...]

OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Étude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la Rectocolite Hémorragique

04/11/2024 - 07:30

OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Étude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la Rectocolite Hémorragique [...]

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

04/11/2024 - 07:30

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis Lusvertikimab met the primary [...]

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

04/11/2024 - 07:30

QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of [...]

PAT : Mise à disposition du Rapport Financier Semestriel 2024

04/11/2024 - 08:00

Vandœuvre-lès-Nancy, le 04 novembre 2024 – 08 : 00 (CET) Communiqué de presse Pour diffusion immédiate Mise à disposition du Rapport Financier Semestriel 2024 Plant Advanced Technologies ( Euronext Growth™- Paris - ISIN [...]

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

04/11/2024 - 08:00

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD [...]

Tessellate BIO Announces Appointment of Lara Boyd as Chief Business Officer

04/11/2024 - 10:00

AMSTERDAM and STEVENAGE, United Kingdom, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment [...]

Trading by management and close relations of management

04/11/2024 - 10:08

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of [...]

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

03/11/2024 - 22:00

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting [...]

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

03/11/2024 - 23:03

MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid [...]

KFSHRC & Lilly Collaborate in Alzheimer’s Early Detection

03/11/2024 - 16:37

RIYADH, Saudi Arabia, Nov. 03, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia signed an MoU today to improve Alzheimer’s patient care. The Memorandum [...]

Optimal Breathing Holds its Annual Black Friday Sale

02/11/2024 - 13:32

FORT MILL, S.C., Nov. 02, 2024 (GLOBE NEWSWIRE) -- Optimal Breathing will hold its annual Black Friday Sale online at www.optimalbreathing.com , starting November 1, 2024. This sale will offer customers a flat 15% OFF [...]

Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités

02/11/2024 - 11:18

L’inclusion est en cours pour les essais d’enregistrement de phase III, pour l’évaluation du pétosemtamab en association avec le pembrolizumab en traitement de 1re intention, et pour l’évaluation du pétosemtamab en [...]

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/11/2024 - 22:26

NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

01/11/2024 - 22:30

OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure [...]

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

01/11/2024 - 22:30

Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted [...]

HeartFlow Announces New Decision from Centers for Medicare & Medicaid Services Boosting CCTA Reimbursement and Access

01/11/2024 - 23:14

— Hospital Outpatient Prospective Payment System reimbursement rate doubled, expanding access to CCTA and supporting the technology’s superior accuracy and efficiency in cardiac care — New payment rates also confirmed [...]